Source: Pharmaceutical Technology
This marks South Korea as the fourth nation to approve the treatment after the US, China and Japan.
It is claimed to be the first and only treatment demonstrated to lower disease progression and slow down cognitive and functional decline.
See Also:South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s Source: Pharmaceutical Technology
EC approves Celltrion’s Omlyclo for allergic conditions Source: Pharmaceutical Technology
Eisai is overseeing the development and regulatory submissions for LEQEMBI globally, with joint commercialisation and promotion of the product alongside Biogen. Eisai retains the final decision-making authority. In South Korea, Eisai Korea will manage the distribution and information provision activities related to LEQEMBI. The FDA’s approval of LEQEMBI was based on the data from Phase III Clarity AD clinical trial. The trial met its primary endpoint and all key secondary endpoints with statistically significant results. Eisai also filed applications for lecanemab’s approval in 13 countries and regions, including the European Union. In the US, a supplemental biologics license application (sBLA) for intravenous maintenance dosing was submitted in March this year.
Additionally, the rolling submission of a biologics license application (BLA) for a subcutaneous injection formulation began recently under fast track status, aiming to enhance patient convenience.